In Vivo Probes for Studying Induction and Inhibition of Cytochrome P450 Enzymes in Humans

Drug-Drug Interactions, Second Edition

Volumn , Issue , 2019, Pages 581-642

  Wilkinson, Grant R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79956158224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780429131967-14     Document Type: Chapter

References (330)

1. Gillette JR. Keynote address: man, mice, microsomes, metabolites, and mathematics— 40 years after the revolution. Drug Metab Rev 1995; 27:1-44.
2. Griese EU, Zanger UM, Bradermanns U, et al. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.
3. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johnson EF, Waterman MR, eds. Cytochrome P450, Part B: Methods in Enzymology. San Diego, CA: Academic Press, 1996; 272:210-218.
4. Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science 1968; 161:72-73.
5. Park BK. Assessment of urinary 63-hydroxycortisol as an in vivo index of mixedfunction oxygenase activity. Br J Clin Pharmacol 1981; 12:97-102.
6. Wilkinson GR. Prediction of interpatient variability of drug metabolizing ability. In: Wilkinson GR, Rawlins MD, eds. Drug Metabolism and Disposition: Considerations in Clinical Pharmacology. Lancaster, PA: MTP Press, 1985, 183-209.
7. Waxman DJ, Attisano C, Guengerich FP, et al. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6P-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263:424-436.
8. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6P-hydroxyCortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989; 28:373-387.
9. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IHA (CYP3A) activity. Clin Pharmacol Ther 1992; 52:265-273.
10. Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and Cortisol. Clin Pharmacol Ther 1992; 51:18-23.
11. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54:621-629.
12. Kinirons MT, O'Shea D, Groopman JD, et al. Route of administration does not explain the lack of correlation between putative in vivo probes of cytochrome P4503A. Br J Clin Pharmacol 1994; 37:501P-502P.
13. Seidegard J, Dahlstrom K, Kullberg A. Effect of grapefruit juice on urinary 6p-hydroxycortisol/cortisoi excretion. Clin Exp Pharmacol Physiol 1998; 25:379-381.
14. Kovacs SJ, Martin DE, Everitt DE, et al. Urinary excretion of 6-beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998; 63:617-622.
15. Fleishaker JC, Pearson LK, Peters GR. Induction of tirilazad clearance by phenytoin. Biopharm Drug Dispos 1998; 19:91-96.
16. Monsarrat B, Chatelut E, Royer I, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998; 26:229-233.
17. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47.
18. Jackson PR, Tucker GT, Lennard MS, et al. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986; 22:541-550.
19. Dalen P, Dahl ML, Eichelbaum M, et al. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9:697-706.
20. Inaba T, Otton SV, Kalow W. Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther 1981; 29:218-223.
21. Kaisary A, Smith P, Jacqz E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47:5488-5493.
22. Kiipfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26:753-759.
23. Wedlund PJ, Aslanian WS, McAllister CB, et al. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36:773-780.
24. Kevorkian JP, Michel C, Hofmann U, et al. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 1996; 59:583-592.
25. Girre C, Lucas D, Hispand E, et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47:1503-1508.
26. Frye RF, Adedoyin A, Mauro K, et al. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998; 38:82-89.
27. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1982; 15:521-552.
28. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57:645-655.
29. Lambert GH, Kotake AN, Schoeller D. The C02 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system. Prog Clin Biol Res 1983; 135:119-145.
30. Lane EA, Parashos I. Drug pharmacokinetics and the carbon dioxide breath test. J Pharmacokinet Biopharm 1986; 14:29-49.
31. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57:16-24.
32. Breimer DD, Schellens JHM. A "cocktail" strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sei 1990; 11:223-225.
33. Sanz EJ, Villen T, Alm C, et al. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45:495-499.
34. Schellens JHM, Ghabrial H, van der Wart HHF, et al. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991; 50:520-528.
35. Frye RF, Matzke GR, Adedoyin A, et al. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997; 62:365-376.
36. Endres HGE, Henschel L, Merkel U, et al. Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration. Pharmazie 1996; 51:46-51.
37. Adedoyin A, Frye RF, Mauro K, et al. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 1998; 46:215-219.
38. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3:197-204.
39. Jones DR, Gorski JC, Hamman MA, et al. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl 1996; 678:105-111.
40. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996; 678:113-128.
41. Schmider J, Greenblatt DJ, Fogelman SM, et al. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997; 18:227-240.
42. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73:67-74.
43. Wienkers LC, Wurden CJ, Storch E, et al. Formation of (R)-8-hydroxywarfarin in human liver microsomes—a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996; 24:610-614.
44. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure, Mechanism, and Biochemistry. New York: Plenum, 1995; 473-535.
45. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53:503-514.
46. Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 1996; 27:245-249.
47. Fuhr U, Rost KL, Engelhardt R, et al. Evaluation of caffeine as a test drug for CYPTA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6:159-176.
48. Nagel RA, Dirix LY, Hay liar KM, et al. Use of quantitative liver function tests— caffeine clearance and galactose elimination capacity—after orthotopic liver transplantation. J Hepatol 1990; 10:149-157.
49. Denaro CP, Jacob P III, Benowitz NL. Evaluation of pharmacokinetic methods used to estimate caffeine clearance and comparison with a Bayesian forecasting method. Ther Drug Monit 1998; 20:78-87.
50. Balogh A, Harder S, Vollandt R, et al. Intra-individual variability of caffeine elimination in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1992; 30: 383-387.
51. Rostami-Hodjegan A, Nurminen S, Jackson PR, et al. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6:121-149.
52. Jost G, Wahllander A, von Mandach U, et al. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987; 7:338-344.
53. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35:431-436.
54. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42:157-165.
55. Wahllander A, Mohr S, Paumgartner G. Assessment of hepatic function— comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 1990; 10:129-137.
56. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/ caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4:109-116.
57. Wietholtz H, Voegelin M, Arnaud MJ, et al. Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol 1981; 21:53-59.
58. Kotake AN, Schoeller DA, Lambert GH, et al. The caffeine C02 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32:261-269.
59. Horsmans Y, De Köninck X, Geubel AP, et al. Microsomal function in hepatitis B surface antigen healthy carriers: assessment of cytochrome P450 1A2 activity by the 14C-caffeine breath test. Pharmacol Toxicol 1995; 77:247-249.
60. Rost KL, Brosicke H, Brockmoller J, et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-(N-3-methyl)-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52:170-180.
61. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55:402-411.
62. Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4:38-46.
63. Pons G, Blais JC, Rey E, et al. Maturation of caffeine N-demethylation in infancy: a study using the 13C02 breath test. Pediatr Res 1988; 23:632-636.
64. Fontana RJ, Turgeon DK, Woolf TF, et al. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23:1429-1435.
65. Breen KJ, Bury RW, Calder IV, et al. A (14C) phenacetin breath test to measure hepatic function in man. Hepatology 1984; 4:47-52.
66. Schoeller DA, Kotake AN, Lambert GH, et al. Comparison of the phenacetin and aminopyrine breath tests: effect of liver disease, inducers and cobaltous chloride. Hepatology 1985; 5:276-281.
67. Tang BK, Kadar D, Quian L, et al. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49:648-657.
68. Notarianni LJ, Oliver SE, Dobrocky P, et al. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995; 39:65-69.
69. Denaro CP, Wilson M, Jacob P III, et al. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin Pharmacol Ther 1996; 59:284-296.
70. Tang BK, Zhou Y, Kadar D, et al. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4:117-124.
71. Butler MA, Lange NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-127.
72. Nakajima M, Yokoi T, Mizutani M, et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994; 3:413-421.
73. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics 1995; 5:S65-S69.
74. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in Af-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52:643-658.
75. Kalow W, BK Tang. Caffeine as a metabolic probe: exploration of the enzymeinducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49:44-48.
76. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50:508-519.
77. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561-1568.
78. Carrillo JA, Benftez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994; 55: 293-304.
79. Catteau A, Bechtel YC, Poisson N, et al. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47:423-430.
80. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996; 18:254-262.
81. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes of acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994; 3:675-682.
82. Kilbane AJ, Silbart LK, Manis M, et al. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 1990; 47:470-477.
83. McQuilkin SH, Nierenberg DW, Bresnick E. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. Cancer Epidemiol Biomarkers Prev 1995; 4:139-146.
84. Hardy BG, Lemieux C, Walker SE, et al. Interindividual and intraindividualvariability in acetylation: characterization with caffeine. Clin Pharmacol Ther 1988; 44:152-157.
85. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987; 42:509-513.
86. Rasmussen BB, Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Br J Clin Pharmacol 1997; 43:253-258.
87. Raunio H, Syngelma T, Pasanen M, et al. Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem Pharmacol 1988; 37:3889-3895.
88. Miles JS, McLaren AW, Forrester LM, et al. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxy-lase activity. Biochem J 1990; 267:365-371.
89. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995; 82:689-699.
90. Spracklin DK, Hankins DC, Fisher JM, et al. Cytochrome P4502E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther 1997; 281:400-411.
91. Sadeque AJM, Fisher MB, Korzekwa KR, et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283:698-703.
92. Madan A, Parkinson A, Faiman MD. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram. Drug Metab Dispos 1995; 23:1153-1163.
93. Torchin CD, McNeilly PJ, Kapetanovic IM, et al. Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metab Dispos 1996; 24:1002-1008.
94. Wirz B, Valles B, Parkinson A, et al. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. ISSX Proc 1996; 10:359.
95. Nunoya KI, Yokoi T, Kimura K, et al. (+)-Cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J Pharmacol Exp Ther 1996; 277:768-774.
96. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322-1329.
97. Hadidi H, Zahlsen K, Idle JR, et al. A single amino acid substitution (Leul60His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol 1997; 35:903-907.
98. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29:91-95.
99. Fernandez-Salguero P, Hoffman SM, Cholerton S, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57:651-660.
100. Nunoya K, Yokoi T, Kimura K, et al. A new deleted allele in the human cytochrome P4502A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (-i-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8:239-249.
101. Rao Y, Hoffmann E, Zia M, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping and in vivo effectson smoking. Mol Pharmacol 2000; 58:747-755.
102. Rautio A, Kraul H, Kojo A, et al. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 1992; 2:227-233.
103. Cholerton S, Idle ME, Vas A, et al. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr 1992; 575: 325-330.
104. Iscan M, Rostami H, Iscan M, et al. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol 1994; 47:315-318.
105. Oscarson M, Gullsten H, Rautio A, et al. Genotyping of human cytochrome P4502A6 (CYP2A6), a nicotine C-oxidase. FEBS Letters 1998; 438:201-205.
106. Sotaniemi EA, Lumme P, Arvela P, et al. Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. Therapie 1996; 51:363-366.
107. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol 1994; 46:175-177.
108. Kharasch ED, Hankins DC, Baxter PJ, et al. Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 1998; 64:39-45.
109. Sotaniemi EA, Rautio A, Backstrom M, et al. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 1995; 39:71-76.
110. Hadidi H, Irshaid Y, Vagbo CB, et al. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Eur J Clin Pharmacol 1998; 54:437-441.
111. Egan D, O'Kennedy R, Moran E, et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 1990; 22:503-529.
112. Marshall ME, Mohler JL, Edmonds K, et al. An updated review of the clinical development of coumarin (1,2-benzopyrene) and 7-hydroxycoumarin. J Cancer Res Clin Oncol 1994; 120:S39-S42.
113. Jacob P III, Benowitz NL, Shulgin AT. Recent studies of nicotine metabolism in humans. Pharmacol Biochem Behav 1988; 30:249-253.
114. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282: 1608-1614.
115. Nakajima M, Yamamoto T, Nunoya KI, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996; 277:1010-1015.
116. Benowitz NL, Jacob P III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56:483-493.
117. Perez-Stable EJ, Herrera B, Jacob P III, et al. Nicotine metabolism and intake in Black and White smokers. JAMA 1998; 280:152-156.
118. Benowitz NL, Jacob P III, Sachs DPL. Deficient C-oxidation of nicotine. Clin Pharmacol Ther 1995; 57:590-594.
119. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538.
120. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-376.
121. Henne KR, Gaedigk A, Gupta G, et al. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl 1998; 710:143-148.
122. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63:519-528.
123. Bhasker CR, Miners JO, Coulter S, et al. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-58.
124. McCrea JB, Cribb A, Rushmore T, et al. Phenotypic and genotypic investigations of a healthy volunteer deficiency in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 1999; 65:348-352.
125. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5:389-392.
126. Tassaneeyakul W, Birkett DJ, Pass MC, et al. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br J Clin Pharmacol 1996; 42:774-778.
127. Knodell RG, Hall SD, Wilkinson GR, et al. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship in vivo disposition. J Pharmacol Exp Ther 1987; 241:1112-1119.
128. Veronese ME, Miners JO, Randies D, et al. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990; 47:403-411.
129. Veronese ME, Miners JO, Rees DLP, et al. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993; 3:86-93.
130. Krishnaiah YSR, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole hi healthy subjects. Br J Clin Pharmacol 1994; 37: 205-207.
131. Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995; 58:412-417.
132. Frye RF, Tracy TS, Hutzler JM, et al. Flurbiprofen as a selective in vivo probe of CYP2C9 activity. Clin Pharmacol Ther 2000; 67:109.
133. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin S-hydroxylation. Arch Biochem Biophys 1993; 306:240-245.
134. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S')-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994; 33:1743-1752.
135. Kiipfer A, Branch RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985; 38:414-418.
136. Adedoyin A, Prakash C, O'Shea D, et al. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994; 4:27-38.
137. Ward SA, Helsby NA, Skjelbo E, et al. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 1991; 31:689-692.
138. Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S'-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2:25-31.
139. Sohn DR, Kwon JT, Kim HK, et al. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61:574-582.
140. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62:619-628.
141. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989; 45:348-355.
142. Skjelbo E, Brosen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49:18-23.
143. Nielsen KK, Brosen K, Hansen MGJ, et al. Single-dose kinetics of clomipramine: relationship to the sparteine and 5-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55:518-527.
144. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52:350-358.
145. Dalen P, Alvan G, Wakelkamp M, et al. Formation of meprobamate from carisoprodol is catalyzed by CYP2C19. Pharmacogenetics 1996; 6:387-394.
146. Sindrup SH, Brosen K, Hansen MGJ, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15:11-17.
147. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57:670-677.
148. Ward SA, Walle T, Walle UK, et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 1989; 45:72-79.
149. Lillibridge JH, Lee CA, Pithavala YK, et al. The role of CYP2C19 in the formation of nelfmavir hydroxy-f-butylamide (M8): in vitro/in vivo correlation. ISSX Proc 1998; 13:55.
150. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43:53-76.
151. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994; 269:15419-15422.
152. de Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-598.
153. Brosen K, de Morais SMF, Meyer UA, et al. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytom oxidation phenotype. Pharmacogenetics 1995; 5:312-317.
154. Ferguson RJ, deMorais SMF, Benhamou S, et al. A novel defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284:356-361.
155. Ibeanu GC, Blaisdell J, Ghanayem BI, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8:129-135.
156. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281:604-609.
157. Ibeanu GC, Goldstein JA, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286:1490-1495.
158. Ibeanu GC, Blaisdell J, Ferguson RJ, et al. A novel transversion in intron5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolism of the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999; 290:635-640.
159. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7:59-64.
160. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-537.
161. Masimirembwa C, Bertilsson L, Johnansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57:656-661.
162. Edeki TI, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. Pharmacogenetics 1996; 6: 357-360.
163. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 in phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996; 60:138-144.
164. Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19:483-487.
165. Nakasaura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.
166. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-397.
167. Roh HK, Dahl ML, Johansson I, et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6:441-447.
168. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytom hydroxylation deficiency in a Korean population and the inter-phenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52:160-169.
169. Jacqz E, Hall SD, Branch RA, et al. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 1986; 39:646-653.
170. Lerena A, Valdivielso MJ, Benitez J, et al. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes. Pharmacol Toxicol 1993; 73:46-48.
171. Bluhm RE, Wilkinson GR, Shelton R, et al. Genetically determined drugmetabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 1993; 53:89-95.
172. Tybring G, Nordin J, Bergman T, et al. An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin. Pharmacogenetics 1997; 7:355-360.
173. Wedlund PJ, Sweetman BJ, Wilkinson GR, et al. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987; 15:277-279.
174. Zhang Y, Blouin RA, McNamara PJ, et al. Limitation to the use of the urinary S/Rmephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991; 31: 350-352.
175. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992; 2:241-243.
176. Wedlund PJ, Wilkinson GR. In vivo and in vitro measurement of CYP2C19 activity. In: Johnson EF, Waterman MR, eds. Cytochrome P450, Part B: Methods in Enzymology. San Diego: Academic Press, 1996; 272:105-114.
177. Sanz EJ, Villen T, Aim C, et al. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45:495-499.
178. Setiabudy R, Chiba K, Kusaka M, et al. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992; 33:665-666.
179. Chiba K, Kobayashi K, Manabe K, et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4/-hydroxylation. J Pharmacol Exp Ther 1993; 266:52-59.
180. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36:521-530.
181. Karam WG, Goldstein JA, Lasker JM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996; 24:1081-1087.
182. Sohn DR, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262:1195-1202.
183. Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39:511-518.
184. Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-368.
185. Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19mi inexon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647-653.
186. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57:662-669.
187. Rost KL, Brockmoller J, Esdorn F, et al. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995; 23: 268-277.
188. Setiabudy R, Kusaka M, Chiba K, et al. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 1995; 39:297-303.
189. Ward SA, Watkins WM, Mberu E, et al. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 1989; 27:781-787.
190. Helsby NA, Ward SA, Edwards G, et al. The pharmaco-kinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990; 30:593-598.
191. Brosen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993; 36:105-108.
192. Wanwimolruk S, Pratt EL, Denton JR, et al. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics 1995; 5:193-198.
193. Wanwimolruk S, Thou MR, Woods DJ. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 1995; 40:166-169.
194. Skjelbo E, Mutabingwa TK, Bygbjerg I, et al. Chloro-guanide metabolism in relation to the efficacy in malaria prophylaxis and the .S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996; 59:304-311.
195. Somogyi AA, Reinhard HA, Bochner F. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol 1996; 41:175-179.
196. Basci NE, Bozkurt A, Kortunay S, et al. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 1996; 42: 771-773.
197. Coller JK, Somogyi AA, Bochner F. Association between CYP2C19 genotype and proguanil oxidative polymorphism. Br J Clin Pharmacol 1997; 43:659-660.
198. Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998; 46:499-504.
199. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, et al. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992; 51:507-512.
200. Partovian C, Jacqz-Aigrain E, Keundjian A, et al. Comparison of chlorguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 1995; 58:257-263.
201. Birkett DJ, Rees D, Andersson T, et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by Smephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37:413-420.
202. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990; 46:377-394.
203. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 1997; 37:269-296.
204. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
205. Tucker GT, Silas JH, Iyun AO, et al. Polymorphic hydroxylation of debrisoquine. Lancet 1977; 2:718.
206. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-187.
207. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73: 539-553.
208. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993; 90:11825-11829.
209. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 C YP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
210. Daly AK, Brockmoller J, Broly F, et al. Nomenclature of human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
211. Masimirembwa C, Hasler J, Bertilsson L, et al. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population—reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996; 51:117-122.
212. Iyun AO, Lennard MS, Tucker GT, et al. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40:387-394.
213. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50:308-313.
214. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5:335-346.
215. Bertilsson L, Dahl ML, Sjoqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63.
216. Eiermann B, Edlund PO, Tjernberg A, et al. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Drug Metab Dispos 1998; 26:1096-1101.
217. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
218. Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 1980; 5:557-569.
219. Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype—a major determinant of metoprololol metabolism and response. New Engl J Med 1982; 307: 1558-1560.
220. Clark DWJ. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 1985; 29:342-375.
221. McGourty JC, Silas JH, Lennard MS, et al. Metoprolol metabolism and debrisoquine oxidation polymorphism—population and family studies. Br J Clin Pharmacol 1985; 20:555-566.
222. Sohn DR, Shin SG, Park CW, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32:504-507.
223. Lennard MS, Tucker GT, Silas JH, et al. Differential stereoselective of metoprolol in extensive and poor debrisoquin metabolisers. Clin Pharmacol Ther 1983; 34: 732-737.
224. Sohn DR, Kusaka M, Shin SG, et al. Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two East Asian populations. Ther Drug Monit 1992; 14:184-189.
225. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
226. Basci NE, Bozkurt A, Kayaalp SO, et al. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan. Eur J Drug Metab Pharmacokinet 1998; 23:1-5.
227. Capon DA, Bochner F, Kerry N, et al. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 1996; 60:295-307.
228. Kiipfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986; 16:421-433.
229. Hou ZY, Pickle LW, Meyer PS, et al. Salivary analysis of determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991; 49:410-419.
230. Hu YP, Tang HS, Lane HY, et al. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998; 285:955-960.
231. Dayer P, Leemann T, Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db 1 activity. Clin Pharmacol Ther 1989; 45:34-40.
232. Kerry NL, Somogyi AA, Bochner F, et al. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994; 38:243-248.
233. Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991; 1:143-148.
234. Funck-Brentano C, Thomas G, Jacqz-Algrain E, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992; 263:780-786.
235. Zimmermann T, Schlenk R, Pfaff P, et al. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers. Arzneimittelforschung 1995; 45:41-43.
236. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system—the role of cytochrome P4502D6. Clin Pharmacokinet 1995; 29(suppl 1): 10-19.
237. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects of the metabolism of other drugs. Mayo Clin Proc 1997; 72:835-847.
238. Horai Y, Taga J, Ishizaki T, et al. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol 1990; 29: 111-115.
239. Woolhouse NM, Eichelbaum M, Oates NS, et al. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37:512-521.
240. Simooya O O, Njunju E, Hodjegan AR, et al. Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993; 3:205-208.
241. Droll K, Bruce-Mensah K, Otton SV, et al. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8:325-333.
242. Ritchie JC, Mitchell SC, Smith RL. Sparteine metabolism in a Nigerian population. Drug Metabol Drug Interact 1996; 13:129-135.
243. Lennard MS, Iyun AO, Jackson PR, et al. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
244. Sommers DK, Moncrieff J, Avenant J. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 1989; 8:365-368.
245. Sommers DK, Moncrieff J, Avena JC. Absence of polymorphism of sparteine oxidation in the South African Venda. Hum Exp Toxicol 1991; 10:175-178.
246. Sommers DK, Moncrieff J, Avenant J. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of Southern Africa. Hum Toxicol 1989; 8: 39-43.
247. Sommers DK, Moncrieff J, Avenant J. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of Southern Africa. Human Toxicol 1988; 7:273-276.
248. Masimirembwa D, Persson I, Bertilsson L, et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713-719.
249. Oscarson M, Hidestrand M, Johansson I, et al. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997; 52:1034-1040.
250. Al-Hadidi HF, Irshaid YM, Rawashdeh NM. Metoprolol alpha-hydroxylation is a poor probe for debrisoquine oxidation (CYP2D6) polymorphism in Jordanians. Eur J Clin Pharmacol 1994; 47:311-314.
251. Irshaid YM, Al-Hadidi HF, Latif A, et al. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation. Eur J Clin Metab Pharmacokinet 1996; 21:301-307.
252. Ronis MJJ, Lindros KO, Ingelman-Sundberg M. The CYP2E1 subfamily. In: Ioannides C, ed. Cytochromes P450: Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996:211-239.
253. Uematsu F, Kikuchi H, Ohmachi T, et al. Two common RFLPs of the human CYP2E gene. Nucleic Acids Res 1991; 19:2803.
254. Hu Y, Oscarson M, Johansson I, et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51:370-376.
255. McCarver DG, Byun R, Hines RN, et al. A genetic polymorphism in the regulatory sequence of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998; 152:276-281.
256. Fairbrother KS, Grove J, de Waziers I, et al. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8:543-552.
257. Carriere V, Berthou F, Baird S, et al. Human cytochrome P450 2E1 (CYP2E1): from genotype of phenotype. Pharmacogenetics 1996; 6:203-211.
258. Powell H, Kitteringham NR, Pirmohamed M, et al. Expression of cytochrome P4502E1 (CYP2E1) in human liver: assessment of mRNA, genotype and phenotype. Pharmacogenetics 1998; 8:411-421.
259. Kim RB, Yamazaki H, Chiba K, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996; 279: 4-11.
260. Lucas D, Menez C, Girre C, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolisminhealthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5:298-304.
261. Le Marchand L, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 1999; 8:495-500.
262. Peter R, Bocker R, Beaune PH, et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 1990; 3:566-573.
263. Carriere V, Goasduff T, Ratanasavanh D, et al. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1994; 6:852-857.
264. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 1995; 23:438-440.
265. Ono S, Hatanaka T, Hotta H, et al. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5:141-148.
266. Gorski JC, Jones DR, Wrighton SA, SD Hall. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997; 27: 243-256.
267. O'Shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56:359-367.
268. Lucas D, Menez JF, Berthou F. Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. In: Johnson EF, Waterman MR, eds. Cytochrome P450, Part B: Methods in Enzymology. San Diego, CA: Academic Press, 1996; 272: 115-123.
269. Kharasch ED, Thummel KE, Mhyre J, et al. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P4502E1. Clin Pharmacol Ther 1993; 53:643-650.
270. Eap CB, Schnyder C, Besson J, et al. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin Pharmacol Ther 1998; 64:52-57.
271. Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998; 64:144-149.
272. Zand R, Nelson SD, Slattery JT, et al. Inhibition and induction of cytochrome P4502El-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54:142-149.
273. O'Shea D, Kim RB, Wilkinson GR. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 1997; 43:99-103.
274. Gebhardt AC, Lucas D, Menez JF, et al. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 1997; 26:957-961.
275. Dilger K, Metzler J, Bode JC, et al. CYP2E1 activity in patients with alcoholic liver disease. J Hepatol 1997; 27:1009-1014.
276. Dupont I, Lucas D, Clot P, et al. Cytochrome P4052E1 inducibility and hydroxyethyl radical formation among alcoholics. J Hepatol 1998; 28:564-572.
277. Lucas D, Menez C, Girre C, et al. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 1995; 19:362-366.
278. Kim RB, O'Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone—a putative measure of CYP2E1 activity. Pharmacogenetics 1994; 4:162-165.
279. Dreisbach AW, Ferencz N, Hopkins NE, et al. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin Pharmacol Ther 1995; 58: 498-505.
280. Vesell ES, DeAngelo Seaton T, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 1995; 5: 53-57.
281. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430.
282. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27:99-127.
283. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13:129-134.
284. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacol Res 1999; 16:408-414.
285. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
286. Fleming CM, Branch RA, Wilkinson GR, et al. Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 1992; 41: 975-980.
287. May DG, Porter J, Wilkinson GR, et al. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994; 55:492-500.
288. May DG, Arns PA, Richards WO, et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992; 51:689-700.
289. Fleming CM, Kaisary A, Wilkinson GR, et al. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 1992; 2: 128-134.
290. Fleming CM, Persad R, Kaisary A, et al. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 1994; 4:199-207.
291. Branch RA, Chern HD, Adedoyin A, et al. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995; 5:S97-S102.
292. May DG, Black CM, Olsen NJ, et al. Scleroderma is associated with differences in individual routes of metabolism: a study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther 1990; 48:286-295.
293. Black C, May G, Csuka ME, et al. Activity of oxidative routes of metabolism of debrisoquine, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease. Clin Pharmacol Ther 1992; 52:659-667.
294. Stein CM, Kinirons MT, Pincus T, et al. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996; 59: 47-51.
295. Mitra AK, Thummel KE, Kalhorn TF, et al. Metabolism of dapsone to its hydroxylamine by cytochrome P-450 2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58:556-566.
296. Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995; 40:531-538.
297. Kinirons MT, Krivoruk Y, Wilkinson GR, et al. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. Br J Clin Pharmacol 1999; 47:223-224.
298. Watkins PG, Hamilton TA, Annesley TM, et al. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990; 48:120-129.
299. Turgeon DK, Normolle DP, Leichtman AB, et al. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992; 52:471-478.
300. Turgeon DK, Leichtman AB, Lown KS, et al. P4503A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994; 56: 253-260.
301. Turgeon DK, Leichtman AB, Blake DS, et al. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test: a prospective study in renal transplant recipients. Transplantation 1994; 57: 1736-1741.
302. Cheng CL, Smith DE, Carver PL, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997; 61:531-543.
303. Wagner D. CYP3A4 and the erythromycin breath test. Clin Pharmacol Ther 1998; 64:129-130.
304. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989; 83:688-697.
305. Krivoruk Y, Kinirons MT, Wood AJJ, et al. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56: 608-614.
306. Schuetz EG, Yasuda K, Arimori K, et al. Human MDR1 and mouse mdrla P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 1998; 350:340-347.
307. Chelvan P, Hamilton-Miller JMT, Brumfitt W. Biliary excretion of erythromycin after parenteral administration. Br J Clin Pharmacol 1979; 8:233-235.
308. Jamis-Dow CA, Pearl ML, Watkins PB, et al. Predicting drug interactions in vivo from experiments in vitro: human studies with paclitaxel and ketoconazole. Am J Clin Oncol 1997; 20:592-599.
309. Tateishi T, Graham SG, Krivoruk Y, et al. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test. Br J Clin Pharmacol 1995; 40: 411-412.
310. Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology 1993; 17:230-235.
311. Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450DIA4. Mol Pharmacol 1989; 36:89-96.
312. Gorski JC, Hall SD, Jones DR, et al. Regioselective biotransformation of midazolam by members of the human cytochrome P4503A (CYP3A) subfamily. Biochem Pharmacol 1994; 47:1643-1653.
313. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-556.
314. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastro-intestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59:491-502.
315. MacGiichrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986; 27:190-195.
316. Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29:272-277.
317. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60:14-24.
318. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intra-individual hepatic P4503A variability after liver transplantation. J Pharmacol Exp Ther 1994; 271: 557-566.
319. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59:7-13.
320. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55:481-485.
321. Backman JT, Olkkola KT, Neuvonen PJ. Azithromycin does not increase plasma concentrations of oral midazolam. Int J Clin Pharmacol Ther 1995; 33:356-359.
322. Mattila MJ, Vanakoski J, Idanpaan-Heikkla JJ. Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 1994; 47:49-52.
323. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995; 40:270-272.
324. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64:133-143.
325. McCrea J, Prueksaritanont T, Gertz BJ, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam (MDZ) as in vivo probes for CYP3A activity. J Clin Pharmacol Ther 1999; 39:1212-1220.
326. Ekins S, VandenBraden M, Ring BJ, et al. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7:165-179.
327. Code EL, Crespi CL, Penman BW, et al. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997; 25:985-993.
328. Ekins S, VandenBraden M, Ring BJ, et al. Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 1998; 286: 1253-1259.
329. Ko JW, Desta Z, Flockhart DA. Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 1998; 26:775-778.
330. Stevens JC, White RB, Hsu SH, et al. Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J Pharmacol Exp Ther 1997; 282:1389-1395.